120 related articles for article (PubMed ID: 2533138)
1. Effect of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on tPA-induced thrombolysis in a rabbit model of femoral arterial thrombosis.
Fujita T; Hasan S; Storer BL; Shebuski RJ
Fundam Clin Pharmacol; 1989; 3(6):643-53. PubMed ID: 2533138
[TBL] [Abstract][Full Text] [Related]
2. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
Shebuski RJ; Smith JM; Storer BL; Granett JR; Bugelski PJ
J Pharmacol Exp Ther; 1988 Aug; 246(2):790-6. PubMed ID: 3136245
[TBL] [Abstract][Full Text] [Related]
3. Effect of thromboxane synthase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis.
Shebuski RJ; Storer BL; Fujita T
Thromb Res; 1988 Dec; 52(5):381-92. PubMed ID: 3146820
[TBL] [Abstract][Full Text] [Related]
4. Combination of the thromboxane receptor antagonist, sulotroban (BM 13.177; SK&F 95587), with streptokinase: demonstration of thrombolytic synergy.
Kopia GA; Kopaciewicz LJ; Ohlstein EH; Horohonich S; Storer BL; Shebuski RJ
J Pharmacol Exp Ther; 1989 Sep; 250(3):887-95. PubMed ID: 2528630
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)- ethylidene]-6,11-dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate in a canine model of femoral thrombosis.
Higo K; Karasawa A; Kubo K
Arzneimittelforschung; 1991 Dec; 41(12):1251-5. PubMed ID: 1815525
[TBL] [Abstract][Full Text] [Related]
6. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries.
Vandeplassche G; Hemans C; Van de Water A; Xhonneux R; Wouters L; Van Ammel K; De Clerck F
Circ Res; 1991 Aug; 69(2):313-24. PubMed ID: 1830517
[TBL] [Abstract][Full Text] [Related]
8. Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator.
Matsuno H; Uematsu T; Umemura K; Takiguchi Y; Wada K; Nakashima M
Br J Pharmacol; 1992 Jul; 106(3):533-8. PubMed ID: 1387025
[TBL] [Abstract][Full Text] [Related]
9. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
10. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
[TBL] [Abstract][Full Text] [Related]
11. The PGI2-analogue iloprost and the TXA2-receptor antagonist sulotroban synergistically inhibit TXA2-dependent platelet activation.
Stürzebecher S; Witt W
Prostaglandins; 1988 Dec; 36(6):751-60. PubMed ID: 2469101
[TBL] [Abstract][Full Text] [Related]
12. Blockade of thromboxane/endoperoxide receptor-mediated responses in the pulmonary vascular bed of the cat by sulotroban.
Nossaman BD; McMahon TJ; Ragheb MS; Ibrahim IN; Babycos CR; Hood JS; Kadowitz PJ
Eur J Pharmacol; 1992 Mar; 213(1):1-7. PubMed ID: 1379928
[TBL] [Abstract][Full Text] [Related]
13. Hirudin and sulotroban improve coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary artery thrombosis.
Martin U; Sponer G; Strein K
Int J Hematol; 1992 Oct; 56(2):143-53. PubMed ID: 1421176
[TBL] [Abstract][Full Text] [Related]
14. A study of the use of the thromboxane A2 antagonist, sulotroban, in combination with streptokinase for local thrombolysis in patients with recent peripheral arterial occlusions: clinical effects, platelet function and fibrinolytic parameters.
Lonsdale RJ; Heptinstall S; Westby JC; Berridge DC; Wenham PW; Hopkinson BR; Makin GS
Thromb Haemost; 1993 Feb; 69(2):103-11, 123. PubMed ID: 8456421
[TBL] [Abstract][Full Text] [Related]
15. Irreversible inhibition of the TXA2/PGH2 receptor of human platelets by a photoaffinity ligand.
Zehender H; Witte EC; Wolff HP; Patscheke H
Biochem Pharmacol; 1988 Feb; 37(3):491-5. PubMed ID: 2962585
[TBL] [Abstract][Full Text] [Related]
16. The pharmacological profile of the thromboxane A2 antagonist BM 13.177. A new anti-platelet and anti-thrombotic drug.
Stegmeier K; Pill J; Müller-Beckmann B; Schmidt FH; Witte EC; Wolff HP; Patscheke H
Thromb Res; 1984 Aug; 35(4):379-95. PubMed ID: 6385334
[TBL] [Abstract][Full Text] [Related]
17. Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo.
Fitzgerald DJ; Doran J; Jackson E; FitzGerald GA
J Clin Invest; 1986 Feb; 77(2):496-502. PubMed ID: 3003161
[TBL] [Abstract][Full Text] [Related]
18. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
Yao SK; Ober JC; Ferguson JJ; Anderson HV; Maraganore J; Buja LM; Willerson JT
Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin H2/thromboxane A2 pathway in platelet aggregation and activity of Dahl salt-sensitive rat--a sulotroban study.
Somova L
Methods Find Exp Clin Pharmacol; 1996 Jun; 18(5):309-13. PubMed ID: 8817465
[TBL] [Abstract][Full Text] [Related]
20. Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis.
Mellott MJ; Connolly TM; York SJ; Bush LR
Thromb Haemost; 1990 Dec; 64(4):526-34. PubMed ID: 2128137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
